Physician profile
Aaron A Westphal
NPI 1164479960
$824.78
in general payments reported to CMS, 2019-2025
11 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2022: $134 · 2023: $128 · 2024: $93.13 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.91 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.90 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $147.53 | 2022-2025 | Ilumya, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $56.62 | 2019-2023 | |
| Janssen Biotech, INC. | $55.94 | 2019-2025 | Tremfya |
| Pfizer INC. | $43.75 | 2019-2023 | |
| Leo Pharma INC. | $31.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.12 | 2019 | |
| Lilly USA, LLC | $20.49 | 2025 | Ebglyss |
| Arcutis Biotherapeutics, INC. | $18.32 | 2024 | Zoryve |
| Ucb, INC. | $17.86 | 2025 | Bimzelx |
| Celgene Corporation | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Westphal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.